Skip to main content

One-Hour Training Improves Documentation to Diagnose, Treat Tardive Dyskinesia

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

TUESDAY, July 18, 2023 -- An annual one-hour Abnormal Involuntary Movement Score (AIMS) training session improves documentation to recognize and treat tardive dyskinesia in the psychiatry outpatient clinic, according to a study recently published in Cureus.

Arindam C. Chakrabarty, M.D., from the Southern Illinois University School of Medicine in Springfield, and colleagues followed a Lean Six Sigma quality improvement model, using the steps of define, measure, analyze, improve, and control. Reasons for AIMS nondocumentation were assessed among psychiatry attendings and residents, and preferred solutions to increase compliance were ranked. AIMS documentation compliance was examined prior to and after implementation of improvements in a random sample of patient charts for individuals on antipsychotic medications.

The researchers found that implementing a one-hour AIMS training session was the most highly ranked solution. Compared with preintervention, a random sample of 60 patient charts showed that significantly more patients had AIMS documented three months postintervention (87 versus 3 percent).

"A one-hour educational intervention increased the rates of screening from 3 to 87 percent," the authors write. "This is an important intervention in view of the nature of the side effects, its prevalence, and the recent approval of effective medications for treatment."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted July 2023

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.